Pure Global

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients - Trial NCT06313970

Access comprehensive clinical trial information for NCT06313970 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06313970
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06313970
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Study Focus

Pancreatic Cancer

QL1706

Interventional

drug

Sponsor & Location

Fudan University

Timeline & Enrollment

Phase 2

Apr 15, 2024

Apr 15, 2026

50 participants

Primary Outcome

Objective response rate (ORR)

Summary

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of
 QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line
 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

ICD-10 Classifications

Malignant neoplasm of pancreas
Malignant neoplasm: Pancreas, unspecified
Malignant neoplasm: Head of pancreas
Malignant neoplasm: Tail of pancreas
Malignant neoplasm: Other parts of pancreas

Data Source

ClinicalTrials.gov

NCT06313970

Non-Device Trial